Neofect, a Kosdaq-listed company dedicated to rehab medicine, said on Wednesday its partner company Ybrain has completed filing for marketing approval of what would be the world’s first commercially available electroceutical to treat depression.

The application is based on Phase 3 clinical trial data of a transcranial direct current stimulation (tDCS) module equipped in Ybrain’s electroceutical platform. In the study involving 65 patients with mild and moderate depressive disorder, most of the patients who used the platform for 30 minutes daily for six weeks showed improvement in depressive symptoms, and more than 50 percent in the treatment group recovered their normal mental state.

International Journal of Neuropsychopharmacology from International College of Neuropsychopharmacology (CINP) said Ybrain’s platform is advantageous in safety and portability, recommending the use of it with Evidence Level A (definitely effective) for patients with depressive symptoms.

Ybrain`s platform is the industry`s smallest portable and wearable electroceutical designed to block overuse through electronic prescription by a medical doctor, Neofect said, adding it will seek contracts for the platform service with domestic hospitals and clinics after marketing approval.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]